source
- CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trialCG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
- Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trialHelus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…